ZTS

Zoetis Inc. Class A Common Stock (ZTS) | Rumor.io

Zoetis

ZTS

Attention (50-day avg)0.03%

Attention rank (50-day avg)#233

Bullish sentiment (50-day avg)35%

Price to earnings ratio11.6

Market capitalization29.5B

Earnings per share6.13

Dividend yield (TTM)2.99%

Revenue (annual)9.5B

Net income (annual)2.7B

Social

What share of all stock conversation is about ZTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.02	0.01% -0.01	0.01% -0.03	0.03% +0.02

Sep 25

Zoetis Inc. ($ZTS) has a 3% dividend yield, up from a 10-year average of 1%, with a 17.5% CAGR in dividend growth over the past decade.
The company has responded to its share price crash with huge buybacks, 12% over the past 12 months alone.
Analysts estimate Zoetis' fair value is 96, with a model suggesting the market is pricing the company roughly flat free cash flow for the next ten years.

Generated by AI

Sentiment

Of the messages about ZTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	13.98% -11.87	33.2% -27.16	51.41% -41.13
Bearish	100% 0	86.02% +11.87	66.8% +27.16	48.59% +41.13

Bullish· Jul 21

Zoetis Inc. (ZTS) has a dominant market position, making it an attractive investment despite its current low price.
The company's dividend yield of around 3% at the current price provides a relatively stable income stream for investors.
The ongoing price decline for nearly 5 years creates a low entry point for ZTS, making it a potentially undervalued investment opportunity.

Bearish· Jun 9

Zoetis Inc. ($ZTS) has seen no return on investment since June 2018, despite doubling its earnings during that time.
The company's flat stock price has been eroded by inflation, which has risen by around 35% since June 2018.
The disconnect between Zoetis' stagnant stock price and its doubling earnings since June 2018 is "pretty wild" and "kinda crazy".

Generated by AI

Topics

Of the messages about ZTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	26.76%	43.72%
Technical Analysis	100%	100%	14.81%	2.87%
Announcements	0%	0%	1.31%	0.77%
Macro	0%	0%	52.68%	44.83%
Earnings	0%	0%	4.44%	7.79%
Controversies	0%	0%	0%	0.02%

Earnings· May 7

Zoetis $ZTS reported Q1 2026 earnings and revenue, with EPS of $1.53, down from $1.62 expected, and revenue of $2.3B, in line with expectations.
The company revised FY26 revenue guidance to $9.68–$9.96B and adjusted EPS to $6.85–$7.00, down from $7.03 expected.
Zoetis stock fell 21.5% after the earnings release, with the company citing a challenging market environment and intensified competition in pet care sectors.

Announcements· Nov 5

Zoetis Inc. (ZTS) announced a 2-hour training and certification program for Librela by December 15, expecting a spike in January orders.
The company's top 5 drugs account for 74% of profit, with patents extending to 2036, and a pipeline that drops a $400M drug every 9 months.
Zoetis' Q3 2025 earnings call transcript revealed a downward revision to full-year revenue and organic growth range, driving a 5.5% stock sell-off.

Macro· Jun 9

$ZTS has been flat since June 2018, with a 0% return, despite earnings doubling over the same period.
Inflation has eaten away around 35% of purchasing power since June 2018, which is significantly higher than the company's earnings growth.
The contrast between $ZTS's flat price and its doubling earnings, alongside high inflation, is considered "wild" and "pretty crazy" by some market observers.

Generated by AI

Community

Of the messages about ZTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.07%	72.74%	22.17%	21.41%
Newcomers	2.93%	27.26%	77.83%	78.59%

Regulars· Aug 6

Zoetis Inc. reported Q2 2026 earnings, with revenue of $2.5B (flat YoY) and adj. EPS of $1.87 (+5% YoY).
The company cut its FY26 guidance, with revenue expected to be $9.12B-$9.32B (vs. est. $9.73B) and adj. net income organic operational growth of -1% to -5%.
The U.S. companion animal segment continues to weaken, down 11% YoY, while the livestock segment remains strong, up 23% YoY.

Newcomers· Sep 25

The price of $ZTS has been volatile, with a recent drop to $71.33 and a predicted fair value of $96.
Newcomers to the stock are discussing the company's recent Q2 earnings, which showed a loss to a competitor and a patent cliff, leading to concerns about the company's future.
Some newcomers are expressing frustration with the stock's performance, with one user joking about it being a "POS" and another suggesting it may be going bankrupt, while others are more optimistic, with one user suggesting a potential merger with another company.

Generated by AI

News

Zoetis Inc. stock underperforms Tuesday when compared to competitors

14h agoMarketWatch

Zoetis Inc. stock outperforms competitors on strong trading day

4d agoMarketWatch

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.

5d agouk.finance.yahoo.com

Also Discussed

Investors talking about ZTS also mention

#	Name	Attention
1	IDEXX Laboratories, Inc.IDXX	0%0
2	Elanco Animal Health IncELAN	0%new
3	Cintas CorporationCTAS	0%new
4	Mondelēz International, Inc. Class A Common StockMDLZ	0%+0
5	Phibro Animal Health Corporation Class A Common StockPAHC	0%0
6	PETQ - PetIQ, Inc.	——
7	HSKA - Heska Corporation	——
8	Danaher Corp.DHR	0.02%+0.02
9	Rollins Inc.ROL	0.03%new
10	Adicet Bio, Inc. Common StockACET	0%-0.01

Zoetis Inc. Class A Common Stock

Healthcare
Drug Manufacturers - Specialty & Generic

Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock. Zoetis develops and markets products used by veterinarians, livestock producers, and pet owners across companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Its portfolio includes parasiticides, dermatology treatments, pain and sedation products, anti-infectives, diagnostic tools, genetic tests, and precision animal health solutions. The company also provides reference laboratory services, rapid tests, instruments, and other non-pharmaceutical offerings that support disease detection and animal care. Headquartered in Parsippany, New Jersey, Zoetis operates in the United States and international markets, serving a broad range of animal health needs across clinical, agricultural, and diagnostic settings.

Website

Location

10 Sylvan Way

Parsippany, NJ, 07054

United States

Social

What share of all stock conversation is about ZTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.02	0.01% -0.01	0.01% -0.03	0.03% +0.02

Sep 25

Zoetis Inc. ($ZTS) has a 3% dividend yield, up from a 10-year average of 1%, with a 17.5% CAGR in dividend growth over the past decade.
The company has responded to its share price crash with huge buybacks, 12% over the past 12 months alone.
Analysts estimate Zoetis' fair value is 96, with a model suggesting the market is pricing the company roughly flat free cash flow for the next ten years.

Generated by AI

Sentiment

Of the messages about ZTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	13.98% -11.87	33.2% -27.16	51.41% -41.13
Bearish	100% 0	86.02% +11.87	66.8% +27.16	48.59% +41.13

Bullish· Jul 21

Zoetis Inc. (ZTS) has a dominant market position, making it an attractive investment despite its current low price.
The company's dividend yield of around 3% at the current price provides a relatively stable income stream for investors.
The ongoing price decline for nearly 5 years creates a low entry point for ZTS, making it a potentially undervalued investment opportunity.

Bearish· Jun 9

Zoetis Inc. ($ZTS) has seen no return on investment since June 2018, despite doubling its earnings during that time.
The company's flat stock price has been eroded by inflation, which has risen by around 35% since June 2018.
The disconnect between Zoetis' stagnant stock price and its doubling earnings since June 2018 is "pretty wild" and "kinda crazy".

Generated by AI

Topics

Of the messages about ZTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	26.76%	43.72%
Technical Analysis	100%	100%	14.81%	2.87%
Announcements	0%	0%	1.31%	0.77%
Macro	0%	0%	52.68%	44.83%
Earnings	0%	0%	4.44%	7.79%
Controversies	0%	0%	0%	0.02%

Earnings· May 7

Zoetis $ZTS reported Q1 2026 earnings and revenue, with EPS of $1.53, down from $1.62 expected, and revenue of $2.3B, in line with expectations.
The company revised FY26 revenue guidance to $9.68–$9.96B and adjusted EPS to $6.85–$7.00, down from $7.03 expected.
Zoetis stock fell 21.5% after the earnings release, with the company citing a challenging market environment and intensified competition in pet care sectors.

Announcements· Nov 5

Zoetis Inc. (ZTS) announced a 2-hour training and certification program for Librela by December 15, expecting a spike in January orders.
The company's top 5 drugs account for 74% of profit, with patents extending to 2036, and a pipeline that drops a $400M drug every 9 months.
Zoetis' Q3 2025 earnings call transcript revealed a downward revision to full-year revenue and organic growth range, driving a 5.5% stock sell-off.

Macro· Jun 9

$ZTS has been flat since June 2018, with a 0% return, despite earnings doubling over the same period.
Inflation has eaten away around 35% of purchasing power since June 2018, which is significantly higher than the company's earnings growth.
The contrast between $ZTS's flat price and its doubling earnings, alongside high inflation, is considered "wild" and "pretty crazy" by some market observers.

Generated by AI

Community

Of the messages about ZTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.07%	72.74%	22.17%	21.41%
Newcomers	2.93%	27.26%	77.83%	78.59%

Regulars· Aug 6

Zoetis Inc. reported Q2 2026 earnings, with revenue of $2.5B (flat YoY) and adj. EPS of $1.87 (+5% YoY).
The company cut its FY26 guidance, with revenue expected to be $9.12B-$9.32B (vs. est. $9.73B) and adj. net income organic operational growth of -1% to -5%.
The U.S. companion animal segment continues to weaken, down 11% YoY, while the livestock segment remains strong, up 23% YoY.

Newcomers· Sep 25

The price of $ZTS has been volatile, with a recent drop to $71.33 and a predicted fair value of $96.
Newcomers to the stock are discussing the company's recent Q2 earnings, which showed a loss to a competitor and a patent cliff, leading to concerns about the company's future.
Some newcomers are expressing frustration with the stock's performance, with one user joking about it being a "POS" and another suggesting it may be going bankrupt, while others are more optimistic, with one user suggesting a potential merger with another company.

Generated by AI

Zoetis

Social

Sep 25

Bullish· Jul 21

Bearish· Jun 9

Earnings· May 7

Announcements· Nov 5

Macro· Jun 9

Regulars· Aug 6

Newcomers· Sep 25

Zoetis Inc. stock underperforms Tuesday when compared to competitors

Zoetis Inc. stock outperforms competitors on strong trading day

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

Zoetis Inc. stock underperforms Thursday when compared to competitors

Zoetis Inc. stock outperforms competitors despite losses on the day

Zoetis stock hits 52-week low at 70.97 USD

Also Discussed

Zoetis Inc. Class A Common Stock

Company Information

Location

Zoetis Inc. stock underperforms Tuesday when compared to competitors

Zoetis Inc. stock outperforms competitors on strong trading day

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

Zoetis Inc. stock underperforms Thursday when compared to competitors

Zoetis Inc. stock outperforms competitors despite losses on the day

Zoetis stock hits 52-week low at 70.97 USD

Also Discussed

Social

Sep 25

Bullish· Jul 21

Bearish· Jun 9

Earnings· May 7

Announcements· Nov 5

Macro· Jun 9

Regulars· Aug 6

Newcomers· Sep 25